RB1 and plasma cell myeloma: Likewise, myeloma cells treated with 20 μM orlistat exhibited a significant reduction in p21 and phospho-pRb levels in myeloma cells, whereas cyclin D1, cyclin D2, cyclin E, CDK4, CDK6, p16 and p27 remained unchanged (Figure 6).